uniQure N.V. (NASDAQ:QURE) had its target price hoisted by Leerink Swann from $17.00 to $19.00 in a report issued on Friday morning, Marketbeat reports. Leerink Swann currently has an outperform rating on the biotechnology company’s stock.
A number of other research analysts have also weighed in on the company. Zacks Investment Research lowered uniQure N.V. from a buy rating to a hold rating in a research note on Thursday, August 24th. Chardan Capital set a $13.00 price target on uniQure N.V. and gave the stock a buy rating in a research note on Sunday, July 23rd. Oppenheimer Holdings, Inc. reissued an outperform rating and set a $17.00 price target on shares of uniQure N.V. in a research note on Friday, June 30th. Finally, ValuEngine lowered uniQure N.V. from a hold rating to a sell rating in a research note on Tuesday, August 1st. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of Hold and an average target price of $13.54.
Shares of uniQure N.V. (NASDAQ:QURE) opened at 18.52 on Friday. uniQure N.V. has a 12-month low of $4.72 and a 12-month high of $21.35. The firm’s market cap is $473.37 million. The company has a 50 day moving average price of $10.15 and a 200 day moving average price of $7.37.
uniQure N.V. (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.05). uniQure N.V. had a negative return on equity of 131.27% and a negative net margin of 289.94%. The business had revenue of $4.94 million for the quarter, compared to analysts’ expectations of $2.92 million. On average, analysts forecast that uniQure N.V. will post ($3.06) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “uniQure N.V. (QURE) Price Target Raised to $19.00 at Leerink Swann” was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.chaffeybreeze.com/2017/10/24/uniqure-n-v-qure-price-target-raised-to-19-00-at-leerink-swann.html.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. increased its holdings in uniQure N.V. by 33.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 58,481 shares of the biotechnology company’s stock valued at $362,000 after purchasing an additional 14,659 shares in the last quarter. Oxford Asset Management acquired a new stake in uniQure N.V. in the 1st quarter valued at $100,000. Mangrove Partners acquired a new stake in uniQure N.V. in the 2nd quarter valued at $247,000. Weiss Multi Strategy Advisers LLC increased its holdings in uniQure N.V. by 266.7% in the 1st quarter. Weiss Multi Strategy Advisers LLC now owns 55,000 shares of the biotechnology company’s stock valued at $318,000 after purchasing an additional 40,000 shares in the last quarter. Finally, FMR LLC increased its holdings in uniQure N.V. by 4.1% in the 2nd quarter. FMR LLC now owns 1,560,113 shares of the biotechnology company’s stock valued at $9,656,000 after purchasing an additional 61,650 shares in the last quarter. Hedge funds and other institutional investors own 30.04% of the company’s stock.
uniQure N.V. Company Profile
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with MarketBeat.com's FREE daily email newsletter.